April 30, 2019
Saniona (SANION.ST), a biotech company focused on the treatment of eating disorders and diseases of the central nervous system, announced today that the English version of the Annual report for 2018 is now available on the company’s website www.saniona.com.
For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: firstname.lastname@example.org
The information was submitted for publication, through the agency of the contact person set out above, at 10:15 CEDT on April 30, 2019.
Saniona is a research and development company focused on drugs for diseases of the central nervous system and eating disorders. The company has five programs in clinical development. Saniona intends to develop and commercialize treatments for orphan indications such as Prader-Willi syndrome and hypothalamic obesity on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona has partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and the company’s shares are listed at Nasdaq Stockholm Small Cap (SANION.ST). Read more at www.saniona.com.